



ISSN: 1478-6419 (Print) 1478-6427 (Online) Journal homepage: http://www.tandfonline.com/loi/gnpl20

New cytotoxic bufadienolides from the roots and rhizomes of *Helleborus thibetanus* Franch

Yuze Li, Huawei Zhang, Xiaofei Liang, Bei Song, Xudong Zheng, Rui Wang, Li Liu, Xiaomei Song & Jianli Liu

To cite this article: Yuze Li, Huawei Zhang, Xiaofei Liang, Bei Song, Xudong Zheng, Rui Wang, Li Liu, Xiaomei Song & Jianli Liu (2018): New cytotoxic bufadienolides from the roots and rhizomes of *Helleborus thibetanus* Franch, Natural Product Research, DOI: <u>10.1080/14786419.2018.1543687</u>

To link to this article: <u>https://doi.org/10.1080/14786419.2018.1543687</u>

÷

View supplementary material oxdots



Published online: 27 Dec 2018.

Submit your article to this journal oxdot T

<u>lılı</u>	Article views:	12
	Article views:	12



View Crossmark data 🗹



Check for updates

New cytotoxic bufadienolides from the roots and rhizomes of *Helleborus thibetanus* Franch

Yuze Li^{a#}, Huawei Zhang^{b#}, Xiaofei Liang^b, Bei Song^a, Xudong Zheng^a, Rui Wang^a, Li Liu^a, Xiaomei Song^b and Jianli Liu^a

^aKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an, China; ^bCollege of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China

ABSTRACT


Three new bufadienolides 14 β , 16 β -dihydroxy-3 β -[β -D-glucopyranosyl-(1 \rightarrow 6)-(β -D-glucopyranosyl)oxy]-5 α -bufa-20, 22-dienolide (1), 14 β -hydroxy-3 β -[β -D-glucopyranosyl-(1 \rightarrow 4)-(β -D-glucopyranosy-l)oxy]-5 α -bufa-20, 22-dienolide (2) and hellebrigenin-3-*O*- β -D-glucosyl-(1 \rightarrow 4)- β -D-glucoside (3), together with eight known bufadienolides (4–11) were isolated from the roots and rhizomes of *Helleborus thibetanus*. Their structures were elucidated by extensive spectroscopic methods and acid hydrolysis. Compounds 1–7 were evaluated for their cytotoxic activity against HCT116, A549 and HepG2 tumor cell lines. Compound 1 exhibited moderate cytotoxicity against HCP116 cells with IC₅₀ value of 15.1 \pm 1.72 μ M. Compounds 5 and 6 exhibited moderate cytotoxicity against HCT116 cells with IC₅₀ values of 15.12 \pm 0.58 μ M and 13.17 \pm 2.34 μ M, respectively.

ARTICLE HISTORY

Received 15 August 2018 Accepted 26 October 2018

KEYWORDS

bufadienolide glycosides; cytotoxic activity; *Helleborus thibetanus* Franch; structure identification



1. Introduction

Helleborus thibetanus Franch., a species in the genus Helleborus of the family Ranunculaceae, is used as an endemic herbal medicine, known as 'Tigencao' or 'Xiao-

[#]Yuze Li and Huawei Zhang contributed equally to this work.

CONTACT Xiaomei Song Songxiaom@126.com; Jianli Liu 🖂 jlliu@nwu.edu.cn

Supplemental data for this article can be accessed at https://doi.org/10.1080/14786419.2018.1543687.

 $[\]ensuremath{\mathbb{C}}$ 2018 Informa UK Limited, trading as Taylor & Francis Group




Figure 1. Structures of compounds 1–11.

tao-er-gi', in the Qinba Mountains of Shaanxi Province in China (Song and Liu 2011). The roots and rhizomes of H. thibetanus are commonly used as folk medicine to treat cystitis, urethritis, sores and traumatic injury (An et al. 2013; Yang et al. 2010). Previous phytochemical investigation on Helleborus illustrated that steroids including bufadienolides, phytoecdystones and steroidal saponins (Bassarello et al. 2008; Braca et al. 2004; Meng et al. 2001; Muzashvili et al. 2011; Tsiftsoglou et al. 2018) were the main components. Pharmacological studies suggested that this plant possesses antitumour, antibacterial, immune-regulation and cytotoxic properties (Littmann et al. 2008; Rosselli et al. 2009). Previous studies disclosed the presence of bufadienolides, spirostanol glycosides, spirostanol sulfonate, pregane and phytoecdystones in the rhizomes of H. thibetanus (Yang et al. 2010; Zhang et al. 2016a; Zhang et al. 2016b; Zhang et al. 2017). The bufadienolides of H. thibetanus had both A/B cis and A/B trans ring fusion modes, and some of them were found to exhibited potent antitumour activity. (Cheng et al. 2014; Ma et al. 2018). As part of our research project to explore more diverse bioactive leading compounds from the medicinal herbs of Qinba mountains of China (Chai et al. 2014; Li et al. 2015; Song et al. 2015), the chemical constituents and pharmacological studies of *H. thibetanus* were studied, and three new bufadienolides 14β , 16β -dihydroxy-3 β -[β -D-glucopyranosyl-(1 \rightarrow 6)-(β -D-glucopyranosyl)oxy]-5 α -bufa-20,22-dienolide (1), 14β -hydroxy- 3β -[β -D-glucopyranosyl-($1 \rightarrow 4$)-(β -D-glucopyranosyl)oxy]- 5α -bufa-20, 22-dienolide (2) and hellebrigenin-3- $O-\beta$ -D-glucosyl- $(1\rightarrow 4)-\beta$ -D-glucoside (3), along with eight known bufadienolides 16β -hydroxyhellebrigenin-3-O- α -L-rhamnoside (4) (Watanabe et al. 2003), hellebrigenin-3- $O-\beta$ -D-glucoside (**5**) (Watanabe et al. 2003), deglucohellebrin (**6**) (Watanabe et al. 2003), hellebrin (**7**) (Yang et al. 2010), 14β hydroxy- 3β -(β -D-glucopyranosyloxy)- 5α -bufa-20, 22-dienolide (**8**) (Cheng et al. 2014), 14 β -hydroxy-3 β -[β -D-glucopyranosyl-(1 \rightarrow 6)-(β -D-glucopyranosyl)oxy]-5 α -bufa-20, 22dienolide (**9**) (Zhang et al. 2014), 14β , 16β -dihydroxy- 3β -(β -D-glucopyranosyloxy)- 5α bufa-20, 22-dienolide (**10**) (Cheng et al. 2014), 14 β , 16 β -dihydroxy-3 β -[β -D-glucopyranosyl- $(1 \rightarrow 4)$ - $(\beta$ -D-glucopyranosyloxy)]-5 β -bufa-20, 22-dienolide (**11**) (Yang et al. 2010) (Figure 1) were isolated from the rhizomes of *H. thibetanus*. Their structures were

elucidated on the basis of extensive spectroscopic analysis. Compounds **1–7** were evaluated for their cytotoxic activity against HCT116, A549 and HepG2 tumor cell lines.

2. Results and discussion

Compound 1 was isolated as a white amorphous powder. Its molecular formula was determined as $C_{36}H_{54}O_{15}$ from the HR-ESI-MS at m/z 749.3364 $[M + Na]^+$ (calcd C36H54O15Na 749.3360). Its IR spectrum revealed absorption bands for hydroxyl (3383 cm^{-1}) and carbonyl groups (1711 cm^{-1}) . The ¹H and ¹³C NMR spectra of **1** indicated the presence of a 2H-pyran-2-one unit [δ_{H} 6.34 (1H, d, J=9.7 Hz, H-23), 7.54 (1H, d, J = 1.6 Hz, H-21), 8.55 (1H, dd, J = 2.5, 9.8 Hz, H-22); δ_{C} 113.1, 119.9, 151.1, 151.8, 162.8], two angular methyls [$\delta_{\rm H}$ 0.68 (3H, s, H-19), 1.02 (3H, s, H-18); $\delta_{\rm C}$ 12.7, 17.8], two oxygenated methines [δ_{H} 4.08 (1H, H-3), 4.82 (1H, t, J = 5.5 Hz, H-16); δ_{C} 78.0, 73.0], one oxygenated quaternary carbon (δ_c 85.0) and two anomeric signals [δ_H 5.01 (1H, d, J = 7.8 Hz, H-1'), 5.18 (1H, d, J = 7.8 Hz, H-1"); δ_{C} 102.9, 105.9]. These evidences indicated that compound 1 possessed a bufadienolide skeleton. The ¹H and ¹³C NMR spectroscopic data of **1** were similar to those of the known compound 3β , 14β , 16β trihydroxy-5 α -bufa-20, 22-dienolide (Zhang et al. 2014), except for the obvious downfield shift of C-3 ($\delta_{C-3} = +$ 7.1), which resulted from glycosylation shifts. The β -configuration (Zhang et al. 2012) of the glucose was deduced from the relative large coupling constants of the anomeric protons ($J = 7.8 \, \text{Hz}$). The two glucosyl moieties were identified as D-glucose by acid hydrolysis of 1, followed by TLC comparison with a reference compound and optical rotation determination (Hudson and Dale 2002). In addition, the HMBC correlation (Table S1 and Figure S1) between H-1' (δ_{H} 5.01) and C-3 ($\delta_{\rm C}$ 78.0), as well as between H-1" ($\delta_{\rm H}$ 5.18) and C-6' ($\delta_{\rm C}$ 70.7) indicated the terminal Glc was linked at C-6 of the inner Glc, which was linked at C-3 of the aglycone. Meanwhile, in the NOESY spectrum, the NOE correlations of H-3/H-1a, H-2a, H-4a and H-5; H-19/H-1b, H-2b, H-4b and H-8 were observed and the lack of correlation between H-5 and H-19, confirming the α -configuration of H-3 and H-5 and the sugar residue to be located at the 3β -position. A key NOE correlation of H-16/H-12a showed the β -configuration of 16-OH. Thus, the structure of **1** was assigned as 14β , 16β -dihydroxy- 3β -[β -D-glucopyranosyl-($1 \rightarrow 6$)-(β -D-glucopyranosyl)oxy]- 5α -bufa-20, 22-dienolide.

Compound **2** was isolated as a white amorphous powder. Its molecular formula was determined as $C_{36}H_{54}O_{14}$ from the HR-ESI-MS at *m/z* 711.3588 [M + H]⁺ (calcd $C_{36}H_{55}O_{14}$ 711.3592). The ¹H and ¹³C NMR spectra of **2** indicated the presence of a 2H-pyran-2-one unit [δ_{H} 6.38 (1H, d, J = 9.7 Hz, H-23), 7.49 (1H, brs, H-21), 8.26 (1H, dd, J = 1.3, 9.7 Hz, H-22); δ_{C} 115.5, 123.7, 147.9, 149.6, 162.4], two angular methyls [δ_{H} 0.66 (3H, s, H-19), 0.89 (3H, s, H-18); δ_{C} 12.4, 17.4], one oxygenated methines [δ_{H} 4.01 (1H, H-3), δ_{C} 77.6], one oxygenated quaternary carbon (δ_{C} 84.6) and two anomeric signals [δ_{H} 5.03 (1H, d, J = 7.8 Hz, H-1'), 5.23 (1H, d, J = 7.8 Hz, H-1''); δ_{C} 102.1, 105.2]. These evidences indicated that compound **2** possessed a bufadienolide skeleton. Comparison of the NMR, HR-ESI-MS data of **2** and **1**, compound **2** exihibited spectroscopic features similar to those of **1**, except sugar chain difference and an absence of 16-OH. The proton and carbon NMR signals of [δ_{H} 2.49 (1H, ca., H-15a), 2.16 (1H, ca., H-15b); δ_{C} 43.6], [δ_{H} 4.82 (1H, t, J = 5.5 Hz, H-16); δ_{C} 73.0] and [δ_{H} 2.82 (1H, d, J = 7.7 Hz, H-17); δ_{C} 59.5]

in **1**, were replaced by $[\delta_{\rm H} 1.87 (1\text{H}, \text{ca., H-15a}), 1.99 (1\text{H}, \text{ca., H-15b}); \delta_{\rm C} 33.1], <math>[\delta_{\rm H} 2.15 (1\text{H}, \text{ca., H-16a}), 1.86 (1\text{H}, \text{ca., H-16b}); \delta_{\rm C} 29.7]$ and $[\delta_{\rm H} 2.47 (1\text{H}, \text{dd}, J = 6.1, 9.3 \text{ Hz}, \text{H-17}); \delta_{\rm C} 51.7]$ in **2**, which was supported by ¹H - ¹H COSY, HMQC, HMBC and NOESY spectra. In addition, the HMBC correlation between H-1' ($\delta_{\rm H} 5.03$) and C-3 ($\delta_{\rm C} 77.6$), as well as between H-1" ($\delta_{\rm H} 5.23$) and C-4' ($\delta_{\rm C} 81.8$) indicated the terminal Glc was linked at C-4 of the inner Glc, which was linked at C-3 of the aglycone. Similarly as compound **1**, the results of the acid hydrolysis procedure and analysis of detail NOESY spectra data showed (Figure S2) the structure of compound **2** was deduced as 14β -hydroxy- 3β -[β -D-glucopyranosyl-($1 \rightarrow 4$)-(β -D-glucopyranosyl)oxy]- 5α -bufa-20, 22-dienolide.

Compound 3 was isolated as a white amorphous powder. Its molecular formula was determined as $C_{36}H_{52}O_{16}$ from the HR-ESI-MS at m/z 763.3155 $[M + Na]^+$ (calcd $C_{36}H_{52}O_{16}Na$ 763.3153). The ¹H and ¹³C NMR spectra of **3** indicated the presence of a 2H-pyran-2-one unit [$\delta_{\rm H}$ 6.36 (1H, d, J = 9.6 Hz, H-23), 7.48 (1H, d, J = 1.6 Hz, H-21), 8.25 (1H, dd, J = 2.5, 9.7 Hz, H-22); δ_{C} 115.8, 123.5, 147.9, 149.9, 162.6], one aldehyde hydrogen [$\delta_{\rm H}$ 10.45 (1H, s, H-19); $\delta_{\rm C}$ 209.1], one angular methyl [$\delta_{\rm H}$ 0.89 (3H, s, H-18); $\delta_{\rm C}$ 17.5], one oxygenated methine [$\delta_{\rm H}$ 4.08 (1H, H-3); $\delta_{\rm C}$ 73.6], two oxygenated quaternary carbons ($\delta_{\rm C}$ 73.9, 84.7) and two anomeric signals [$\delta_{\rm H}$ 5.04 (1H, d, J = 7.9 Hz, H-1'), 5.22 (1H, d, J = 7.9 Hz, H-1"); δ_c 101.4, 105.6]. These evidences indicated that compound **3** possessed a bufadienolide skeleton. The ¹H and ¹³C NMR spectroscopic data of **3** were similar to those of 5, except for the sugar chain difference. And the HMBC correlation between H-1' ($\delta_{\rm H}$ 5.04) and C-3 ($\delta_{\rm C}$ 73.6), as well as between H-1" ($\delta_{\rm H}$ 5.22) and C-4' $(\delta_{\rm C}$ 82.1) indicated the terminal Glc was linked at C-4 of the inner Glc, which was linked at C-3 of the aglycone. The β -configuration (Zhang et al. 2012) of the glucose was deduced from the relative large coupling constants of the anomeric protons (J = 7.9 Hz). The two glucosyl moieties were identified as D-glucose by acid hydrolysis of **3**, followed by TLC comparison with a reference compound and optical rotation determination (Hudson and Dale 2002). Meanwhile, in the NOESY spectrum (Figure S3), the NOE correlations of H-3/H-4, H-4a/H-7a and H-9, and H-19/H-8, indicated α -axial configurations of H-3 and β -orientation of H-19, 3-OH and 5-OH, which supported the A/B cis ring junction pattern. Thus, the structure of 3 was formulated as hellebrigenin-3-O- β -D-glucosyl-(1 \rightarrow 4)- β -D-glucoside.

Compounds 1–7 were evaluated for their cytotoxic activity against HCT116, A549 and HepG2 tumor cell lines, 5-fluorouracil was used as positive control. As shown in Table S2, compound 1 exhibited moderate cytotoxicity against HepG2 cells with IC_{50} value of $15.1 \pm 1.72 \,\mu$ M, compounds 5 and 6 exhibited moderate cytotoxicity against HCT116 cells with IC_{50} values of $15.12 \pm 0.58 \,\mu$ M and $13.17 \pm 2.34 \,\mu$ M, respectively. Compounds 3, 5–7 shared the same aglycone, but exhibited different activities. This suggested that the structural differences such as the category and the number of the oligosaccharide at C-3 played a role in terms of antitumor effect.

3. Experimental

3.1. General experimental procedures

Optical rotation indices were determined in methanol on a Rudolph Autopol II digital polarimeter (Rudolph, Hackettstown, NJ, USA). The IR spectra were recorded on a

TENSOR-27 instrument (Bruker, Rheinstetten, Germany). ESI-MS was performed on a Quattro Premier instrument (Waters, Milford, MA, USA). The HR-ESI-MS spectra were recorded on an Agilent Technologies 6550 Q-TOF (Santa Clara, CA, USA). 1D and 2D NMR spectra were recorded on Bruker-AVANCE 400 instrument (Bruker, Rheinstetten, Germany) with TMS as an internal standard. The analytical HPLC was performed on a Waters 2695 Separations Module coupled with a 2996 Photodiode Array Detector and a Accurasil C18 column (4.6 mm \times 250 mm, 5 mm particles, Ameritech, Chicago, IL, USA). Semipreparative HPLC was performed on a system comprising an LC-6AD pump (Shimadzu, Kyoto, Japan) equipped with a SPD-20A UV detector and a Ultimate XB-C18 (10 mm \times 250 mm, 5 mm particles) or YMC-Pack-ODS-A (10 mm \times 250 mm, 5 mm particles) or SMC-Pack-ODS-A (10 mm \times 250 mm, 5 mm particles). D101 was from Sunresin New Materials Co. Ltd. (Xi'an, China). Silica gel was purchased from Qingdao Haiyang Chemical Group Corporation (Qingdao, China).

3.2. Plant material

The roots and rhizomes of *H. thibetanus* were collected from the Taibai region of Qinba Mountains in Shaanxi Province, China, in June 2016, and identified by senior experimentalist Jitao Wang. A voucher specimen (herbarium No. 20160915) has been deposited in the Medicinal Plants Herbarium (MPH), Shaanxi University of Chinese Medicine, Xianyang, China.

3.3. Extraction and isolation

The air-dried and powdered underground parts of *H. thibetanus* (15 kg) were extracted with 60% EtOH (15L) three times at 80 °C. After removing the solvent, the concentrated residue was successively partitioned with petroleum ether and n-BuOH. The n-BuOH extract (500 g) was subjected to column chromatography (CC) on silica gel with gradient elution (CHCl₃-MeOH-H₂O, 100:0:0-65:35:10), which yielded ten fractions (Fr.1-10). Fr.3 (80 g) was subjected to column chromatography (CC) on silica gel, eluting with gradient solvent system (CHCl₃-MeOH, 100:0-50:50) to yield five fractions (Fr.3-1-Fr.3-5). Fr.3-3 (220 mg) were purified by HPLC with CH₃CN-H₂O (35:65) as mobile phase to afford **4** (50 mg), **5** (62 mg), **6** (14 mg). Fr.4 (60 g) was subjected to column chromatography (CC) on silica gel, eluting with gradient solvent system (CHCl₃-MeOH, 100:0-50:50) to yield six fractions (Fr.4-1-Fr.4-6). Fr.4-2 (220 mg) were purified by HPLC (YMC-Pack-ODS-A, 10 mm \times 250 mm, 5 μ m particles, flow rate: 1.0 mL·min⁻¹) with CH₃CN-H₂O (30:70) as mobile phase to afford 8 (13 mg), 10 (11 mg), 9 (15 mg) and 11 (21 mg). Fr.6 (65 g) were loaded on a silica gel column and eluted with a gradient solvent system (CHCl₃-MeOH, 100:0-50:50) to yield four fractions (Fr.6-1-Fr.6-4). Fr.6-2 was purified by HPLC with CH₃CN-H₂O (25:75) as the mobile phase to obtain 2 (100 mg) and 7 (12 mg). Fr.6-4 was purified by HPLC with CH₃CN-H₂O (27:73) as the mobile phase to obtain 1 (10 mg) and **3** (8 mg).

3.3.1. 14 β , 16 β -dihydroxy-3 β -[β -D-glucopyranosyl-(1 \rightarrow 6)-(β -D-glucopyranosyl)oxy]-5 α -bufa-20, 22-dienolide (1)

A white amorphous powder, $[\alpha]_D^{27.2}$ -16.9 (*c* 1.1, MeOH), IR (KBr) v_{max} : 3382, 2941, 1711, 1055. ¹H-NMR (400 MHz, pyridine-*d*₅) and ¹³C-NMR (100 MHz, pyridine-*d*₅) spectral data, see Table S1; *m/z* 749.3364 [M + Na]⁺ (calcd. for C₃₆H₅₄O₁₅Na 749.3360).

3.3.2. 14 β -hydroxy-3 β -[β -D-glucopyranosyl-(1 \rightarrow 4)-(β -D-glucopyranosyl)oxy]-5 α -bufa-20, 22-dienolide (2)

A white amorphous powder, $[\alpha]_D^{26.8}$ -36.0 (*c* 1.3, MeOH), IR (KBr) v_{max} : 3382, 2943, 1709, 1056. ¹H-NMR (400 MHz, pyridine-*d*₅) and ¹³C-NMR (100 MHz, pyridine-*d*₅) spectral data, see Table S1; *m/z* 711.3588 [M + H]⁺ (calcd. for C₃₆H₅₅O₁₄ 711.3592).

3.3.3. Hellebrigenin-3-O- β -D-glucosyl-(1 \rightarrow 4)- β -D-glucoside (3)

A white amorphous powder, $[\alpha]_D^{27.0}$ -19.5 (*c* 0.7, MeOH), IR (KBr) v_{max} : 3407, 2944, 1715, 1630, 1056. ¹H-NMR (400 MHz, pyridine- d_5) and ¹³C-NMR (100 MHz, pyridine- d_5) spectral data, see Table S1; *m*/*z* 763.3155 [M + Na]⁺ (calcd. for $C_{36}H_{52}O_{16}Na$ 763.3153).

3.4. Acid hydrolysis of compounds 1-3 and absolute sugar configuration determination

The solutions of compounds **1** (4 mg), **2** (3 mg) and **3** (5 mg) were hydrolyzed with 2N HCl (5 mL) for 5 h at 80 °C, respectively. The reaction mixtures were concentrated and dried by N₂, and then water (5 mL) was added and the mixtures were extracted with EtOAc (3 × 5 mL). The aqueous layers of **1–3** were subjected to CC over silica gel eluted with MeCN-H₂O (8:1) to yield D-glucose, which was determined by TLC comparison (MeCN-H₂O, 6:1) with the authentic sugar and the optical rotation determination $[\alpha]_D^{20.0} + 49.2$ (*c* 0.16, H₂O).

3.5. Cytotoxicity experiments

The cytotoxic activity assays towards the HCT116, A549 and HepG2 tumor cell lines were measured by the MTT method *in vitro*, using 5-fluorouracil as positive control. Briefly, 1×10^4 mL⁻¹ cells were seeded into 96-well plates and allowed to adhere for 24 h. Compounds **1–7** were dissolved in DMSO and diluted with complete medium to six concentration levels (from 0.001 mmol·L⁻¹ to 0.3 mmol·L⁻¹) for inhibition rate determination. After incubation at $37 \degree C$ for 4 h, the supernatant was removed before adding DMSO (100 µL) to each well. 5-Fluorouracil (5-Fu) was used as positive control. The inhibition rate (IR) and IC₅₀ were calculated. Values are mean ± SD, n = 3, ** p < 0.01 vs. DMEM control. Compounds **1–7** showed cytotoxicity against human HCT116, A549 and HepG2 cell lines; the IC₅₀ values are shown in Table S2.

4. Conclusion

Three new bufadienolides 14 β , 16 β -dihydroxy-3 β -[β -D-glucopyranosyl-(1 \rightarrow 6)-(β -D-glucopyranosyl)oxy]-5 α -bufa-20, 22-dienolide (**1**), 14 β -hydroxy-3 β -[β -D-glucopyranosyl-(1 \rightarrow 4)-(β -D-glucopyranosyl)oxy]-5 α -bufa-20, 22-dienolide (**2**) and hellebrigenin-3-*O*- β -D-glucosyl-(1 \rightarrow 4)- β -D-glucoside (**3**), together with eight known bufadienolides (**4–11**) were isolated from the roots and rhizomes of *H. thibetanus*. Compounds **1**, **5** and **6** showed moderate cytotoxicity.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This project was financially supported by the National Natural Science Foundations of China (grant number 81503195); the Natural Science Foundation of Shaanxi Province (grant number 2016JQ8030); Key R&D Program of Shaanxi Province (grant number 2017SF-360); and the project was supported by the Open Research Fund of Key Laboratory of Basic and New Herbal Medicament Research, Shaanxi university of Chinese medicine (grant number 2017KF02, 17JS030).

References

- An Q, Lu NW, Dong YM. 2013. Chromatographic fingerprint coupled with hierarchical clustering analysis and principal component analysis for quality evaluation and original discrimination of rhizomes of *Helleborus thibetanus* Franch by HPLC-DAD. Anal Meth UK. 5:5775–5784.
- Bassarello C, Muzashvili T, Skhirtladze A, Kemertelidze E, Pizza C, Piacente S. 2008. Steroidal glycosides from the underground parts of *Helleborus caucasicus*. Phytochemistry. 69:1227–1233.
- Braca A, Prieto JM, De Tommasi N, Tome F, Morelli I. 2004. Furostanol saponins and quercetin glycosides from the leaves of *Helleborus viridis* L. Phytochemistry. 65:2921–2928.
- Chai J, Song XM, Wang X, Mei QB, Li Z, Cui JC, Tang ZS, Yue ZG. 2014. Two new compounds from the roots and rhizomes of *Trillium tschonoskii*. Phytochem Lett. 10:113–117.
- Cheng W, Tan YF, Tian HY, Gong XW, Chen KL, Jiang RW. 2014. Two new bufadienolides from the rhizomes of *Helleborus thibetanus* with inhibitory activities against prostate cancer cells. Nat Prod Res. 28:901–908.
- Hudson CS, Dale JK. 2002. Studies on the forms of d-glucose and their mutarotation. J Am Chem Soc. 39:320–328.
- Li YZ, Wang X, He H, Zhang DD, Jiang Y, Yang XJ, Wang F, Tang ZS, Song XM, Yue ZG. 2015. Steroidal saponins from the roots and rhizomes of *Tupistra chinensis*. Molecules. 20: 13659–13669.
- Littmann L, Rossner S, Kerek F, Steinkasserer A, Zinser E. 2008. Modulation of murine bone marrow-derived dendritic cells and B-cells by MCS-18 a natural product isolated from *Helleborus purpurascens*. Immunobiol. 213:871–878.
- Ma L, Meng YY, Tu CH, Cao XQ, Wang HY, Li Y, Man SL, Zhou J, Li M, Liu ZX, et al. 2018. A cardiac glycoside HTF-1 isolated from *Helleborus thibetanus* Franch displays potent *in vitro* anticancer activity via caspase-9, MAPK and PI3K-Akt-mTOR pathways. Eur J Med Chem. 158: 743–752.
- Meng Y, Whiting P, Sik V, Rees HH, Dinan L. 2001. Ecdysteroids and bufadienolides from *Helleborus torquatus* (Ranunculaceae). Phytochemistry. 57:401–407.

8 🕢 Y. LI ET AL.

- Muzashvili T, Perrone A, Napolitano A, Kemertelidze E, Pizza C, Piacente S. 2011. Caucasicosides E-M, furostanol glycosides from *Helleborus caucasicus*. Phytochemistry. 72:2180–2188.
- Rosselli S, Maggio A, Bruno M, Spadaro V, Formisano C, Irace C, Maffettone C, Mascolo N. 2009. Furostanol saponins and ecdysones with cytotoxic activity from *Helleborus bocconei* ssp. intermedius. Phytother Res. 23:1243–1249.
- Song XM, Li YZ, Zhang DD, Jiang Y, Wang W, Song B, Tang ZS, Cui JC, Yue ZG. 2015. Two new spirostanol saponins from the the roots and rhizomes of *Tupistra chinensis*. Phytochem Lett. 13:6–10.
- Song XM, Liu HJ. 2011. Research and Application of "Qi-Medicines" In Taibai Mountains. Beijing: People's Medical Publishing House; p. 17.
- Tsiftsoglou OS, Stefanakis MK, Lazari DM. 2018. Chemical constituents isolated from the rhizomes of *Helleborus odorus* subsp. cyclophyllus (Ranunculaceae). Biochem Syst Ecol. 79:8–11.
- Watanabe K, Mimaki Y, Sakagami H, Yutaka S. 2003. Bufadienolide and spirostanol glycosides from the rhizomes of *Helleborus orientalis*. J Nat Prod. 66:236–241.
- Yang FY, Su YF, Wang Y, Chai X, Han X, Wu ZH, Gao XM. 2010. Bufadienolides and phytoecdystones from the rhizomes of *Helleborus thibetanus* (Ranunculaceae). Biochem Syst Ecol. 38: 759–763.
- Yang FY, Su YF, Zhang X, Tu GZ, Gao XM, Zhang BL. 2010. New spirostanol sulfonate from the rhizomes of *Helleborus thibetanus* (Ranunculaceae). Chem Res Chinese U. 26:746–748.
- Yang J, Zhang YH, Miao F, Zhou L, Sun W. 2010. Two new bufadienolides from the rhizomes of *Helleborus thibetanus* Franch. Fitoterapia. 81:636–639.
- Zhang H, Su YF, Yang FY. 2016a. Four new minor spirostanol glycosides from *Helleborus thibetanus*. Phytochem Lett. 18:213–219.
- Zhang H, Su YF, Yang FY. 2016b. Three new steroidal saponins from *Helleborus thibetanus*. Nat Prod Res. 30:1724–1730.
- Zhang H, Su YF, Yang FY, Gao XM. 2017. New minor spirostanol glycosides from *Helleborus thibetanus*. Nat Prod Res. 31:925–931.
- Zhang H, Su YF, Yang FY, Zhao ZQ, Gao XM. 2014. Two new bufadienolides and one new pregnane from *Helleborus thibetanus*. Phytochem Lett. 10:164–167.
- Zhang XD, Chen CX, Yang JY, Ni W, Liu HY. 2012. New minor spirostane glycosides from *Ypsilandra thibetica*. Helv Chim Acta. 95:1087–1093.